A Phase II Study of Crenolanib Besylate Maintenance Following Allogeneic Stem Cell Transplantation in Patients With FLT3-positive Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Crenolanib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 13 Oct 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
- 13 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 10 Jun 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017 as per ClinicalTrials.gov record.